Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
September 10, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
Pending Home Sales Dropped 5.5% in July
August 29, 2024 10:00 ET
|
National Association of Realtors®
WASHINGTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Key Highlights Pending home sales fell 5.5% in July.Month over month, contract signings declined in all four U.S. regions.Compared to one year ago,...
National Hydropower Association Celebrates National Hydropower Day, Pushes for Greater Recognition and Much-Needed Regulatory Reforms
August 22, 2024 12:24 ET
|
National Hydropower Association
Washington, D.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- The National Hydropower Association, America’s leading trade association for the U.S. water power industry, is proudly celebrating National...
Tony Tipton nommé au poste de directeur des opérations États-Unis de Crossject en vue de la commercialisation de ZEPIZURE®, traitement d'urgence dans la prise en charge des crises d’épilepsie
August 19, 2024 11:30 ET
|
CROSSJECT
Communiqué de presse Tony Tipton nommé au poste de directeur des opérations États-Unis de Crossject en vue de la commercialisation de ZEPIZURE®, traitement d'urgence dans la prise en charge des...
Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment
August 19, 2024 11:30 ET
|
CROSSJECT
Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 13, 2024 07:00 ET
|
Praxis Precision Medicines, Inc.
Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of...
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
August 08, 2024 07:00 ET
|
Rapport Therapeutics, Inc.
Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
August 07, 2024 16:11 ET
|
Catalyst Pharmaceuticals, Inc.
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million,...
Pending Home Sales Rose 4.8% in June
July 31, 2024 10:00 ET
|
National Association of Realtors®
WASHINGTON, July 31, 2024 (GLOBE NEWSWIRE) -- Key Highlights Pending home sales intensified 4.8% in June.Month over month, contract signings increased in all four U.S. regions.Compared to one...
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
July 25, 2024 05:00 ET
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...